ReviewClinical and experimental vaccine research2014
Current status of human papillomavirus vaccines.
Review in Clinical and experimental vaccine research, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 1 synthesis or guideline pooled it, 52 citations in OpenAlex.
- Prevalence and genotype distribution of genital human papillomavirus infection in female sex workers in the world: a systematic review and meta-analysis.BMC public health · 2020Pooled it
- Cancer Vaccines: Mechanisms, Clinical Applications, Challenges, and Future Directions in Precision Medicine.Current cancer drug targets · 2026Review
- Novel bioinformatics approaches to design epitope-based vaccine against HIV latency by inquiring CTL epitopes and built-in adjuvants.Scientific reports · 2025Article
- Article
- Human Papillomavirus 16 DNA Methylation Patterns and Investigation of Integration Status in Head and Neck Cancer Cases.International journal of molecular sciences · 2023Article
- Peptide Vaccines as Therapeutic and Prophylactic Agents for Female-Specific Cancers: The Current Landscape.Pharmaceuticals (Basel, Switzerland) · 2023Review
- Antigenic Peptide Prediction From E6 and E7 Oncoproteins of HPV Types 16 and 18 for Therapeutic Vaccine Design Using Immunoinformatics and MD Simulation Analysis.Frontiers in immunology · 2018Article
- Assessing the Importance of Domestic Vaccine Manufacturing Centers: An Overview of Immunization Programs, Vaccine Manufacture, and Distribution.Frontiers in immunology · 2018Review
- Therapeutic Cancer Vaccines-T Cell Responses and Epigenetic Modulation.Frontiers in immunology · 2018Review
- Immunodominant T-Cell Epitopes in the VP1 Capsid Protein of Rhinovirus Species A and C.Journal of virology · 2016Article
- Human papilloma virus in oral cancer.Journal of the Korean Association of Oral and Maxillofacial Surgeons · 2016Review
- HPV Vaccination: Attitude and Knowledge among German Gynecologists.Geburtshilfe und Frauenheilkunde · 2016Article
- Preclinical refinements of a broadly protective VLP-based HPV vaccine targeting the minor capsid protein, L2.Vaccine · 2015Article
- Genetics and vaccines in the era of personalized medicine.Current genomics · 2015Article
- E5 and E6/E7 of high-risk HPVs cooperate to enhance cancer progression through EMT initiation.Cell adhesion & migration · 2015Article
- Sub-acute toxicity study in female ICR mice following repetitive intramuscular injection of cervical cancer vaccines.Environmental health and toxicology · 2014Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cervical cancer is a malignant neoplasm arising from cells that originate in the cervix uteri. It is the second most prevalent cancer among women. It can have several causes; an infection with some type of human papillomavirus (HPV) is the greatest risk factor for cervical cancer. Over 100 types of HPVs have been identified, and more than 40 types of HPVs are typically transmitted through sexual contact and infect the anogenital region. Among these, a number of HPVs types, containing types 16 and 18, are classified as "high-risk" HPVs that can cause cervical cancer. The HPVs vaccine prevents infection with certain species of HPVs associated with the development of cervical cancer, genital warts, and some less common cancers. Two HPVs vaccines are currently on the global market: quadrivalent HPVs vaccine and bivalent HPV vaccine that use virus-like particles as a vaccine antigen. This review discusses the current status of HPVs vaccines on the global market, clinical trials, and the future of HPVs vaccine development.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.